Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy

Zucali, Paolo Andrea, De Pas, Tommaso, Palmieri, Giovannella, Favaretto, Adolfo, Chella, Antonio, Tiseo, Marcello, Caruso, Michele, Simonelli, Matteo, Perrino, Matteo, De Vincenzo, Fabio, Toffalorio, Francesca, Damiano, Vincenzo, Pasello, Giulia, Garbella, Erika, Ali, Marco, Conforti, Fabio, Ottaviano, Margaret, Cioffi, Angela, De Placido, Sabino, Giordano, Laura, Bertossi, Monica, Destro, Annarita, Di Tommaso, Luca, Santoro, Armando·2018·Journal of Clinical Oncology

Abstract

Purpose: No effective salvage treatments are available for patients with advanced/recurrent thymoma (T) or thymic carcinoma (TC) who have progressed after platinum-based chemotherapy. This study evaluated the activity of everolimus in patients with advanced/recurrent T or TC previously treated with cisplatin-containing chemotherapy. Patients and Methods: This was a single-arm, single-stage, open-label, multicenter, phase II trial. Patients received oral everolimus 10 mg/d until disease progression, unacceptable toxicity, or patient refusal. A Fleming phase II trial was designed. The null hypothesis of a true disease control rate (DCR) of 40% was tested against a one-sided alternative of a true DCR of 60% (α = β = 0.10): If disease control were achieved in ≥ 21 of the first 41 evaluable patients, everolimus could be recommended for further evaluation. Progression-free survival, overall survival, and safety were also evaluated. Results: From 2011 to 2013, 51 patients were enrolled (T, n = 32; TC, n = 19). Complete remission was observed in one patient with TC, partial response in five patients (T, n = 3; TC, n = 2), and stable disease in 38 patients (T, n = 27; TC, n= 11), with a DCR of 88% (T,: 93.8%; TC, 77.8%). With a median follow up of 25.7 months, median progression-free survival was 10.1 months (T,: 16.6 months; TC, 5.6 months), and median overall survival was 25.7 months (T, not reached; TC, 14.7 months). Fourteen patients had a serious drug-related adverse event; of these patients, nine permanently discontinued treatment. Three patients died of pneumonitis while in the study. Immunohistochemical positivity for p4E-BP1 or insulin-like growth factor-1 receptor was statistically significantly related to a shorter survival. Conclusion: Everolimus may induce durable disease control in a high percentage of patients with T or TC, albeit with a potential high risk of fatal pneumonitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.74.4078

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 173

Metadata

Authors
Zucali, P. A., De Pas, T., Palmieri, G., Favaretto, A., Chella, A., Tiseo, M., Caruso, M., Simonelli, M., Perrino, M., De Vincenzo, F., Toffalorio, F., Damiano, V., Pasello, G., Garbella, E., Ali, M., Conforti, F., Ottaviano, M., Cioffi, A., De Placido, S., Giordano, L., Bertossi, M., Destro, A., Di Tommaso, L., & Santoro, A.
Venue
Journal of Clinical Oncology
Published
2018-02-01
Volume
36
Issue
4
Pages
342-349
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2613990243
Cited by
173
References
2
FWCI
7.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. https://app.cochat.ai/papers/10.1200/jco.2017.74.4078
The paper
Zucali, P. A., De Pas, T., Palmieri, G., Favaretto, A., Chella, A., Tiseo, M., Caruso, M., Simonelli, M., Perrino, M., De Vincenzo, F., Toffalorio, F., Damiano, V., Pasello, G., Garbella, E., Ali, M., Conforti, F., Ottaviano, M., Cioffi, A., De Placido, S., . . . Santoro, A. (2018). Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.74.4078

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.